Day: February 22, 2024

                                       Silexion’s first generation product, Loder™, successfully tested in a multinational Phase 2a clinical trial in patients with non-resectable pancreatic cancer which harbors an oncogene believed to be a major driver of the cancer In combination with chemotherapy, Loder resulted in a median overall survival (OS) advantage of 9.3 months over chemotherapy alone (22.7 vs 13.4 months) Modi’in, Israel and New York, New York, Feb. 22, 2024 (GLOBE NEWSWIRE) — Moringa Acquisition Corp (Nasdaq: MACA) (“Moringa”), a special purpose acquisition company, today announced it has entered into a business combination agreement with Silexion Ltd. (“Silexion”), a clinical-stage, oncology-focused biotechnology company, that would result in Silexion becoming publicly listed on the Nasdaq. The business combination...

The global Coating Additives market size is expected to reach USD 14.31 billion by 2031 and exhibit a CAGR of 5.10% in the forecast period (2023−2030), according to Skyquest’s latest research report. Environmental regulations and consumer preferences for low-VOC and water-based coatings drive the increasing demand for sustainable and eco-friendly coatings. The need for improved performance characteristics, such as durability, UV resistance, and anti-corrosion properties in coatings, is fueling the market’s growth. Westford USA, Feb. 22, 2024 (GLOBE NEWSWIRE) — SkyQuest’s latest global research of the Coating Additives market shows growing demand for nanotechnology-based additives, which offer enhanced performance and functionality to coatings. The rise of eco-friendly and sustainable coatings is driving the use...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary Clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree SHANTA GOLD LIMITED(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree LONDONMETRIC PROPERTY PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...